Viridian Therapeutics, Inc.\De VRDN
Institutional shares held
82.7 Million
78.9K
calls
417K
puts
Total value of holdings
$1.49B
$1.42M
calls
$7.49M
puts
Market Cap
$717M
39,888,900
Shares Out.
Institutional ownership
207.38%
# of Institutions
184
We take great care to ensure that the data presented and summarized in this overview for Viridian Therapeutics, Inc.\DE is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding VRDN
View all-
Deep Track Capital, LP Greenwich, CT5.38MShares$96.7 Million2.67% of portfolio
-
Commodore Capital LP New York, NY4.88MShares$87.6 Million6.35% of portfolio
-
Black Rock Inc. New York, NY4.77MShares$85.8 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.51MShares$81 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ4.43MShares$79.6 Million7.39% of portfolio
-
Vr Adviser, LLC New York, NY3.88MShares$69.8 Million10.75% of portfolio
-
Fairmount Funds Management LLC Philadelphia, PA3.46MShares$62.2 Million14.83% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD2.9MShares$52 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.84MShares$51.1 Million2.38% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.74MShares$49.3 Million1.79% of portfolio
Latest Institutional Activity in VRDN
Top Purchases
Top Sells
About VRDN
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
Insider Transactions at VRDN
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 10
2025
|
Fairmount Funds Management LLC Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
12,500
+0.36%
|
$150,000
$12.31 P/Share
|
|
Jun 09
2025
|
Fairmount Funds Management LLC Director |
BUY
Exercise of conversion of derivative security
|
Indirect |
1,600
+0.05%
|
$11,200
$7.8 P/Share
|
|
Sep 27
2024
|
Stephen F. Mahoney President and CEO |
BUY
Open market or private purchase
|
Direct |
21,400
+50.0%
|
$492,200
$23.33 P/Share
|
|
Sep 27
2024
|
Thomas W. Beetham Chief Operating Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+45.45%
|
$115,000
$23.41 P/Share
|
|
Sep 13
2024
|
Fairmount Funds Management LLC Director |
BUY
Open market or private purchase
|
Indirect |
1,600,000
+31.71%
|
$28,800,000
$18.75 P/Share
|
|
Mar 28
2024
|
Fairmount Funds Management LLC Director |
BUY
Other acquisition or disposition
|
Indirect |
5,859
+0.32%
|
-
|
|
Mar 28
2024
|
Fairmount Funds Management LLC Director |
SELL
Other acquisition or disposition
|
Indirect |
5,859
-100.0%
|
-
|
|
Jan 22
2024
|
Fairmount Funds Management LLC Director |
BUY
Open market or private purchase
|
Indirect |
476,190
+20.56%
|
$9,999,990
$21.0 P/Share
|
|
Jun 16
2023
|
Lara Meisner Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
27
-0.09%
|
$756
$28.35 P/Share
|
|
Jun 16
2023
|
Lara Meisner Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
27
+0.09%
|
$621
$23.03 P/Share
|
|
Jun 15
2023
|
Lara Meisner Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
2,269
-7.04%
|
$63,532
$28.02 P/Share
|
|
Jun 15
2023
|
Lara Meisner Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
2,269
+6.58%
|
$52,187
$23.03 P/Share
|
|
Jun 06
2023
|
Lara Meisner Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
5,126
-14.61%
|
$128,150
$25.02 P/Share
|
|
Jun 06
2023
|
Lara Meisner Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,126
+12.74%
|
$92,268
$18.51 P/Share
|
|
Jun 05
2023
|
Lara Meisner Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
499
-1.64%
|
$12,475
$25.03 P/Share
|
|
Jun 05
2023
|
Lara Meisner Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
499
+1.61%
|
$8,982
$18.51 P/Share
|
|
Jun 02
2023
|
Lara Meisner Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
1,875
-5.89%
|
$45,000
$24.21 P/Share
|
|
Jun 02
2023
|
Lara Meisner Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
1,875
+5.56%
|
$26,250
$14.0 P/Share
|
|
Apr 12
2023
|
Scott Dunseth Myers Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
4,000
+1.52%
|
$100,000
$25.37 P/Share
|
|
Mar 13
2023
|
Scott Dunseth Myers Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
5,500
+2.11%
|
$159,500
$29.15 P/Share
|
Last 12 Months Summary
Buy / Acquisition
1.64M
Shares
From
4
Insiders
| Open market or private purchase | 1.63M shares |
|---|---|
| Exercise of conversion of derivative security | 14.1K shares |
Sell / Disposition
0
Shares
From
0
Insiders